Acute Myeloid Leukemia: analysis of epidemiological profile and survival rate

详细信息    查看全文

• 作者：Mariana Cardoso de Lima ; ^{marianac_lima@yahoo.com.br" class="auth_mail" title="E-mail the corresponding author} ; Denise Bousfield da Silva ; Ana Paula Ferreira Freund ; Juliana Shmitz Dacoregio ; Tatiana El Jaick Bonif&aacute ; cio Costa ; Imaru&iacute ; Costa ; Daniel Faraco ; Maur&iacute ; cio Laerte Silva
• 关键词：Acute myeloid leukemia ; Leukemia ; Children
• 刊名：Jornal de Pediatria (Versão em Português)
• 出版年：2016
• 出版时间：May-June 2016
• 年：2016
• 卷：92
• 期：3
• 页码：283-289
• 全文大小：551 K

文摘

To describe the epidemiological profile and the survival rate of patients with acute myeloid leukemia (AML) in a state reference pediatric hospital.

Method

r0010">Clinical‐epidemiological, observational, retrospective, descriptive study. The study included new cases of patients with AML, diagnosed between 2004 and 2012, younger than 15 years.

Results

r0015">Of the 51 patients studied, 84% were white; 45% were females and 55%, males. Regarding age, 8% were younger than 1 year, 47% were aged between 1 and 10 years, and 45% were older than 10 years. The main signs/symptoms were fever (41.1%), asthenia/lack of appetite (35.2%), and hemorrhagic manifestations (27.4%). The most affected extra‐medullary site was the central nervous system (14%). In 47% of patients, the white blood cell (WBC) count was below 10,000/mm³ at diagnosis. The minimal residual disease (MRD) was less than 0.1%, on the 15^th day of treatment in 16% of the sample. Medullary relapse occurred in 14% of cases. When comparing the bone marrow MRD with the vital status, it was observed that 71.42% of the patients with type M3 AML were alive, as were 54.05% of those with non‐M3 AML. The death rate was 43% and the main proximate cause was septic shock (63.6%).

Conclusions

r0020">In this study, the majority of patients were male, white, and older than 1 year. Most patients with WBC count < 10,000/mm³ at diagnosis lived. Overall survival was higher in patients with MRD < 0.1%. The prognosis was better in patients with AML‐M3.